Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2019 · 10-Q
Revenue$17.06K$17.06K+19.7% vs Q1 2018 Net Income-$2.34M-$2.34MN/M vs Q1 2018 EPS Diluted-$0.04-$0.04N/M vs Q1 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flow-$728,549N/M Margins · derivedGross margin74.3%−13.7 pt vs Q1 2018
Operating margin-13443.9%+847.2 pt vs Q1 2018
Net margin-13731.2%+5664.5 pt vs Q1 2018
ended Mar 31, 2019 · filed May 15, 2019 · 45 d after period end